Healthcare Stocks Show Overbought Warning Signals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2026
0mins
Should l Buy ACLX?
Source: Benzinga
- Overbought Signals: As of March 4, 2026, Anika Therapeutics Inc (NASDAQ:ANIK) and Arcellx Inc (NASDAQ:ACLX) are identified as major overbought stocks in the healthcare sector, with RSI indicators exceeding 70, signaling caution for investors.
- Momentum Indicator Analysis: The RSI serves as a momentum indicator by comparing a stock's strength on up days versus down days, aiding traders in assessing short-term stock performance; an overbought condition may lead to price corrections, impacting investment decisions.
- Market Reaction Expectations: The emergence of overbought signals may prompt investors to reassess the short-term investment value of these two stocks, potentially leading to capital outflows that could affect stock price movements.
- Industry Trend Observation: The overbought phenomenon in the healthcare sector may reflect excessive optimism in the market towards certain companies, necessitating investors to monitor overall market sentiment and fundamental changes in related stocks to formulate more rational investment strategies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACLX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACLX
Wall Street analysts forecast ACLX stock price to fall
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 114.570
Low
100.00
Averages
113.14
High
130.00
Current: 114.570
Low
100.00
Averages
113.14
High
130.00
About ACLX
Arcellx Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering immunotherapies for patients with cancer and other incurable diseases. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. It is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gilead Acquires Ouro Medicines for $1.675 Billion in Cash
- Acquisition Agreement: Gilead Sciences has announced a definitive agreement to acquire Ouro Medicines for $1.675 billion in cash, plus up to $500 million in contingent milestone payments, indicating a strategic expansion in the autoimmune disease sector.
- New Drug Addition: The acquisition adds OM336 (gamgertamig) to Gilead's inflammation portfolio, a drug that has shown efficacy in severe autoimmune diseases during clinical trials, thereby enhancing Gilead's competitive edge in the biopharmaceutical industry.
- Strategic Collaboration: Gilead plans to enter into a strategic collaboration with Galapagos, which will cover 50% of the upfront costs and milestone payments, while also managing development costs, ensuring resource sharing and risk mitigation between the parties.
- Global Commercialization Rights: Gilead will retain sole worldwide commercialization rights, except in Greater China where Keymed Biosciences holds existing rights, and is expected to generate revenue through royalties of 20% to 23% of net sales, further solidifying its market position.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Investigation Background: Halper Sadeh LLC is investigating companies like Arcellx, Inc., Masimo Corporation, and FONAR Corporation for potential violations of federal securities laws and breaches of fiduciary duties, which may affect shareholder rights.
- Arcellx Transaction: Arcellx is being sold to Gilead Sciences, Inc. for $115.00 per share in cash, plus a contingent value right of $5.00 per share upon achieving certain milestones, raising concerns about the fairness of the deal.
- Masimo Transaction: Masimo Corporation is being sold for $180.00 per share in cash, with terms that may limit superior competing offers, prompting shareholders to be vigilant about their rights.
- FONAR Transaction: FONAR Corporation's sale involves CEO Timothy Damadian and other executives, offering $19.00 per share for Class B common stock and $6.34 per share for Class C common stock, with Halper Sadeh LLC potentially seeking increased consideration.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the acquisition of Talkspace, Inc. by Universal Health Services, Inc., where Talkspace shareholders are set to receive $5.25 per share in cash, potentially providing significant returns for investors.
- UniFirst Acquisition Details: In the transaction between UniFirst Corporation and Cintas Corporation, UniFirst shareholders will receive $155 in cash and 0.7720 shares of Cintas stock per UniFirst share, enhancing overall shareholder value through this strategic deal.
- Arcellx Transaction Outlook: The acquisition of Arcellx, Inc. by Gilead Sciences, Inc. is expected to yield $115 in cash per share for Arcellx shareholders, along with a contingent value right of $5 per share upon achieving specific milestones, creating additional value for investors.
- FONAR Shareholder Rights: In the transaction involving FONAR Corporation, Class B common stockholders will receive $19 per share, while Class C common stockholders will receive $6.34 per share, providing clear cash returns for different classes of shareholders involved in the deal.
See More
Monteverde Law Firm Investigates Mergers for Shareholder Recovery
- Shareholder Recovery Success: Monteverde & Associates has been recognized as a Top 50 firm in the 2025 ISS Securities Class Action Services Report, successfully recovering millions for shareholders, demonstrating its strong capabilities and influence in the securities class action field.
- Ongoing Merger Investigations: The firm is investigating the merger between Quetta Acquisition Corporation and Smart Kreate Group Limited, aiming to protect shareholder interests and further solidify its expertise in mergers and acquisitions.
- Transparent Transaction Terms: In the merger with Gravitics, Inc., shareholders of Non-Invasive Monitoring Systems, Inc. are expected to own 4.5% of the combined company, a transparent structure that helps boost investor confidence.
- Cash Return Commitment: In the transaction with Gilead Sciences, Inc., Arcellx shareholders are set to receive $115 per share in cash plus a contingent value right of $5 per share, ensuring substantial returns for shareholders post-transaction and increasing market interest in the deal.
See More
Cormorant Asset Management Fully Exits Arcellx Stake
- Complete Liquidation: Cormorant Asset Management disclosed on February 17, 2026, that it sold 775,000 shares of Arcellx for approximately $63.63 million, fully liquidating its position and reducing its stake from 4.4% to zero, indicating a complete exit from this investment.
- Market Performance Comparison: Despite Cormorant's exit, Arcellx's stock has surged 60% over the past year, currently priced at $114.51, significantly outperforming the S&P 500's roughly 19% gain during the same period, reflecting strong market confidence in its future potential.
- Company Fundamentals: With a market capitalization of $6.7 billion, Arcellx reported $22.3 million in revenue over the last twelve months, but incurred a net loss of $228.9 million, highlighting the high-risk, high-reward nature of its clinical-stage immunotherapy developments targeting cancer.
- Acquisition Potential: Arcellx recently entered into a takeover agreement with Gilead Sciences, valuing the company at approximately $7.8 billion and offering shareholders $115 per share in cash plus potential additional payments tied to future sales milestones, indicating strong interest from larger pharmaceutical companies in its CAR-T cell therapies, which could accelerate development and commercialization.
See More
Cormorant Asset Management Fully Exits Arcellx Stake
- Complete Liquidation: Cormorant Asset Management sold 775,000 shares of Arcellx in Q4, fully liquidating its position, resulting in a $63.63 million decrease in the fund's quarter-end value, indicating a significant shift in its investment strategy.
- Change in Investment Proportion: Previously, Arcellx accounted for 4.4% of the fund's AUM, and this exit reflects a waning confidence in the company, which may influence future investment decisions by Cormorant.
- Market Reaction: Despite Cormorant's exit leading to losses, Arcellx's stock has surged 80% this year, primarily driven by interest from larger pharmaceutical companies in its next-generation CAR-T cell therapies, highlighting strong market interest.
- Acquisition Agreement Impact: The acquisition agreement with Gilead Sciences, valuing Arcellx at approximately $7.8 billion and offering shareholders $115 per share in cash, could accelerate the development and commercialization of its therapies, although Cormorant's timing of exit missed this potential upside.
See More
Gilead Acquires Ouro Medicines for $1.675 Billion in Cash
- Acquisition Agreement: Gilead Sciences has announced a definitive agreement to acquire Ouro Medicines for $1.675 billion in cash, plus up to $500 million in contingent milestone payments, indicating a strategic expansion in the autoimmune disease sector.
- New Drug Addition: The acquisition adds OM336 (gamgertamig) to Gilead's inflammation portfolio, a drug that has shown efficacy in severe autoimmune diseases during clinical trials, thereby enhancing Gilead's competitive edge in the biopharmaceutical industry.
- Strategic Collaboration: Gilead plans to enter into a strategic collaboration with Galapagos, which will cover 50% of the upfront costs and milestone payments, while also managing development costs, ensuring resource sharing and risk mitigation between the parties.
- Global Commercialization Rights: Gilead will retain sole worldwide commercialization rights, except in Greater China where Keymed Biosciences holds existing rights, and is expected to generate revenue through royalties of 20% to 23% of net sales, further solidifying its market position.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Investigation Background: Halper Sadeh LLC is investigating companies like Arcellx, Inc., Masimo Corporation, and FONAR Corporation for potential violations of federal securities laws and breaches of fiduciary duties, which may affect shareholder rights.
- Arcellx Transaction: Arcellx is being sold to Gilead Sciences, Inc. for $115.00 per share in cash, plus a contingent value right of $5.00 per share upon achieving certain milestones, raising concerns about the fairness of the deal.
- Masimo Transaction: Masimo Corporation is being sold for $180.00 per share in cash, with terms that may limit superior competing offers, prompting shareholders to be vigilant about their rights.
- FONAR Transaction: FONAR Corporation's sale involves CEO Timothy Damadian and other executives, offering $19.00 per share for Class B common stock and $6.34 per share for Class C common stock, with Halper Sadeh LLC potentially seeking increased consideration.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the acquisition of Talkspace, Inc. by Universal Health Services, Inc., where Talkspace shareholders are set to receive $5.25 per share in cash, potentially providing significant returns for investors.
- UniFirst Acquisition Details: In the transaction between UniFirst Corporation and Cintas Corporation, UniFirst shareholders will receive $155 in cash and 0.7720 shares of Cintas stock per UniFirst share, enhancing overall shareholder value through this strategic deal.
- Arcellx Transaction Outlook: The acquisition of Arcellx, Inc. by Gilead Sciences, Inc. is expected to yield $115 in cash per share for Arcellx shareholders, along with a contingent value right of $5 per share upon achieving specific milestones, creating additional value for investors.
- FONAR Shareholder Rights: In the transaction involving FONAR Corporation, Class B common stockholders will receive $19 per share, while Class C common stockholders will receive $6.34 per share, providing clear cash returns for different classes of shareholders involved in the deal.
See More
Monteverde Law Firm Investigates Mergers for Shareholder Recovery
- Shareholder Recovery Success: Monteverde & Associates has been recognized as a Top 50 firm in the 2025 ISS Securities Class Action Services Report, successfully recovering millions for shareholders, demonstrating its strong capabilities and influence in the securities class action field.
- Ongoing Merger Investigations: The firm is investigating the merger between Quetta Acquisition Corporation and Smart Kreate Group Limited, aiming to protect shareholder interests and further solidify its expertise in mergers and acquisitions.
- Transparent Transaction Terms: In the merger with Gravitics, Inc., shareholders of Non-Invasive Monitoring Systems, Inc. are expected to own 4.5% of the combined company, a transparent structure that helps boost investor confidence.
- Cash Return Commitment: In the transaction with Gilead Sciences, Inc., Arcellx shareholders are set to receive $115 per share in cash plus a contingent value right of $5 per share, ensuring substantial returns for shareholders post-transaction and increasing market interest in the deal.
See More
Cormorant Asset Management Fully Exits Arcellx Stake
- Complete Liquidation: Cormorant Asset Management disclosed on February 17, 2026, that it sold 775,000 shares of Arcellx for approximately $63.63 million, fully liquidating its position and reducing its stake from 4.4% to zero, indicating a complete exit from this investment.
- Market Performance Comparison: Despite Cormorant's exit, Arcellx's stock has surged 60% over the past year, currently priced at $114.51, significantly outperforming the S&P 500's roughly 19% gain during the same period, reflecting strong market confidence in its future potential.
- Company Fundamentals: With a market capitalization of $6.7 billion, Arcellx reported $22.3 million in revenue over the last twelve months, but incurred a net loss of $228.9 million, highlighting the high-risk, high-reward nature of its clinical-stage immunotherapy developments targeting cancer.
- Acquisition Potential: Arcellx recently entered into a takeover agreement with Gilead Sciences, valuing the company at approximately $7.8 billion and offering shareholders $115 per share in cash plus potential additional payments tied to future sales milestones, indicating strong interest from larger pharmaceutical companies in its CAR-T cell therapies, which could accelerate development and commercialization.
See More
Cormorant Asset Management Fully Exits Arcellx Stake
- Complete Liquidation: Cormorant Asset Management sold 775,000 shares of Arcellx in Q4, fully liquidating its position, resulting in a $63.63 million decrease in the fund's quarter-end value, indicating a significant shift in its investment strategy.
- Change in Investment Proportion: Previously, Arcellx accounted for 4.4% of the fund's AUM, and this exit reflects a waning confidence in the company, which may influence future investment decisions by Cormorant.
- Market Reaction: Despite Cormorant's exit leading to losses, Arcellx's stock has surged 80% this year, primarily driven by interest from larger pharmaceutical companies in its next-generation CAR-T cell therapies, highlighting strong market interest.
- Acquisition Agreement Impact: The acquisition agreement with Gilead Sciences, valuing Arcellx at approximately $7.8 billion and offering shareholders $115 per share in cash, could accelerate the development and commercialization of its therapies, although Cormorant's timing of exit missed this potential upside.
See More
